HK1202069A1 - Compounds for treating spinal muscular atrophy - Google Patents
Compounds for treating spinal muscular atrophyInfo
- Publication number
- HK1202069A1 HK1202069A1 HK15102661.7A HK15102661A HK1202069A1 HK 1202069 A1 HK1202069 A1 HK 1202069A1 HK 15102661 A HK15102661 A HK 15102661A HK 1202069 A1 HK1202069 A1 HK 1202069A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compounds
- muscular atrophy
- spinal muscular
- treating spinal
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/76—Benzo[c]pyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261591102P | 2012-01-26 | 2012-01-26 | |
| PCT/US2013/023067 WO2013112788A1 (en) | 2012-01-26 | 2013-01-25 | Compounds for treating spinal muscular atrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1202069A1 true HK1202069A1 (en) | 2015-09-18 |
Family
ID=48873933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15102661.7A HK1202069A1 (en) | 2012-01-26 | 2015-03-16 | Compounds for treating spinal muscular atrophy |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9399649B2 (xx) |
| EP (1) | EP2809322B9 (xx) |
| JP (2) | JP6193888B2 (xx) |
| KR (1) | KR102064624B1 (xx) |
| CN (1) | CN104203239B (xx) |
| BR (1) | BR112014018027B1 (xx) |
| CA (1) | CA2862084C (xx) |
| EA (1) | EA028344B1 (xx) |
| ES (1) | ES2733644T3 (xx) |
| HK (1) | HK1202069A1 (xx) |
| MX (1) | MX357834B (xx) |
| PL (1) | PL2809322T3 (xx) |
| WO (1) | WO2013112788A1 (xx) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2797592B1 (en) | 2011-12-30 | 2019-08-28 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| EP2809322B9 (en) * | 2012-01-26 | 2019-10-30 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| SG10201609188WA (en) | 2012-02-10 | 2016-12-29 | Ptc Therapeutics Inc | Compounds for treating spinal muscular atrophy |
| WO2013130689A1 (en) | 2012-03-01 | 2013-09-06 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| US9914722B2 (en) | 2012-03-23 | 2018-03-13 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| WO2014102778A2 (en) * | 2012-12-24 | 2014-07-03 | Ramot At Tel-Aviv University Ltd. | Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same |
| CA2915764A1 (en) | 2013-08-19 | 2015-02-26 | F. Hoffmann-La Roche Ag | Screening method |
| US10195202B2 (en) | 2013-12-19 | 2019-02-05 | Ptc Therapeutics, Inc. | Methods for modulating the amount of RNA transcripts |
| WO2015095446A1 (en) * | 2013-12-19 | 2015-06-25 | Ptc Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| US10882868B2 (en) | 2014-05-15 | 2021-01-05 | Hoffmann-La Roche Inc. | Compounds for treating spinal muscular atrophy |
| US10668171B2 (en) | 2015-05-30 | 2020-06-02 | Ptc Therapeutics, Inc. | Methods for modulating RNA splicing |
| AU2016353961B2 (en) * | 2015-11-12 | 2019-08-29 | F. Hoffmann-La Roche Ag | Compositions for treating spinal muscular atrophy |
| CA3005434A1 (en) | 2015-11-16 | 2017-05-26 | Ohio State Innovation Foundation | Methods and compositions for treating disorders and diseases using survival motor neuron (smn) protein |
| PL3386511T3 (pl) | 2015-12-10 | 2021-11-08 | Ptc Therapeutics, Inc. | Sposoby leczenia choroby huntingtona |
| EP3386978B1 (en) | 2015-12-10 | 2021-01-27 | H. Hoffnabb-La Roche Ag | Bridged piperidine derivatives |
| JP6738044B2 (ja) * | 2016-07-22 | 2020-08-12 | Jnc株式会社 | ベンゾピラン骨格を有する液晶性化合物、液晶組成物、および液晶表示素子 |
| WO2018098446A1 (en) | 2016-11-28 | 2018-05-31 | Ptc Therapeutics, Inc | Methods for modulating rna splicing |
| MX2019014514A (es) | 2017-06-05 | 2020-07-20 | Ptc Therapeutics Inc | Compuestos para tratar la enfermedad de huntington. |
| CN111372611A (zh) | 2017-06-14 | 2020-07-03 | Ptc医疗公司 | 修饰rna剪接的方法 |
| MX2019015580A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| EP3644996B1 (en) | 2017-06-28 | 2023-07-26 | PTC Therapeutics, Inc. | Methods for treating huntington's disease |
| BR122020005073A2 (pt) | 2017-08-04 | 2020-10-13 | Skyhawk Therapeutics, Inc. | Composto, composição farmacêutica e uso do composto |
| EA202092001A1 (ru) | 2018-03-27 | 2021-01-29 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения болезни гентингтона |
| CA3103976A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating huntington's disease |
| EP3814360A1 (en) | 2018-06-27 | 2021-05-05 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| KR20210025625A (ko) * | 2018-06-27 | 2021-03-09 | 리보르나 바이오사이언시스, 아이엔씨. | 척수성 근위축증 예방제 또는 치료제 |
| EP3920915A4 (en) | 2019-02-05 | 2022-10-05 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING SPLICE |
| CN113677344A (zh) | 2019-02-06 | 2021-11-19 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5854142B2 (ja) * | 1975-04-16 | 1983-12-02 | 株式会社興人 | イソカルボスチリル誘導体の製造方法 |
| US5089633A (en) * | 1987-04-28 | 1992-02-18 | Georgia Tech Research Corporation | Substituted isocoumarins |
| US6180625B1 (en) * | 1998-03-24 | 2001-01-30 | Novo Nordisk A/S | Heterocyclic compounds regulating clotting |
| WO2003004458A1 (en) * | 2001-07-03 | 2003-01-16 | Biovitrum Ab | New compounds |
| GB0205281D0 (en) * | 2002-03-06 | 2002-04-17 | Novartis Ag | Organic compounds |
| WO2003104216A1 (en) * | 2002-06-10 | 2003-12-18 | Acadia Pharmaceuticals Inc. | Urotensin ii receptor modulators |
| AR040350A1 (es) * | 2002-06-28 | 2005-03-30 | Vertex Pharma | Inhibidores de caspasa y usos de los mismos |
| JP2004168707A (ja) * | 2002-11-20 | 2004-06-17 | Bayer Cropscience Ag | イソチアゾリルベンゾオキサジン誘導体および病害防除剤 |
| US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
| EP1646615B1 (en) | 2003-06-06 | 2009-08-26 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as modulators of atp-binding cassette transporters |
| WO2006078834A1 (en) | 2005-01-21 | 2006-07-27 | Janssen Pharmaceutica N.V. | Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| KR100781704B1 (ko) * | 2005-04-20 | 2007-12-03 | 에스케이케미칼주식회사 | 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물 |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| US8337941B2 (en) | 2006-07-27 | 2012-12-25 | The Trustees Of Columbia University In The City Of New York | Fluorescent substrates for monoamine transporters as optical false neurotransmitters |
| KR20080091949A (ko) | 2007-04-10 | 2008-10-15 | 에스케이케미칼주식회사 | 락톤형 피리딘 화합물을 포함하는 허혈성 질환의 예방 및치료용 약학조성물 |
| JP5276878B2 (ja) | 2007-09-27 | 2013-08-28 | 富士フイルム株式会社 | ベンゾオキサジノン系化合物の製造方法 |
| US8633019B2 (en) * | 2008-05-27 | 2014-01-21 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| US8986935B2 (en) | 2008-08-13 | 2015-03-24 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| EP2797592B1 (en) | 2011-12-30 | 2019-08-28 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| EP2809322B9 (en) * | 2012-01-26 | 2019-10-30 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| SG10201609188WA (en) | 2012-02-10 | 2016-12-29 | Ptc Therapeutics Inc | Compounds for treating spinal muscular atrophy |
| WO2013130689A1 (en) | 2012-03-01 | 2013-09-06 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| US9914722B2 (en) | 2012-03-23 | 2018-03-13 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
-
2013
- 2013-01-25 EP EP13740919.9A patent/EP2809322B9/en active Active
- 2013-01-25 CN CN201380016999.2A patent/CN104203239B/zh active Active
- 2013-01-25 PL PL13740919T patent/PL2809322T3/pl unknown
- 2013-01-25 BR BR112014018027-0A patent/BR112014018027B1/pt active IP Right Grant
- 2013-01-25 CA CA2862084A patent/CA2862084C/en active Active
- 2013-01-25 WO PCT/US2013/023067 patent/WO2013112788A1/en active Application Filing
- 2013-01-25 EA EA201491412A patent/EA028344B1/ru not_active IP Right Cessation
- 2013-01-25 US US14/373,937 patent/US9399649B2/en active Active
- 2013-01-25 MX MX2014008875A patent/MX357834B/es active IP Right Grant
- 2013-01-25 ES ES13740919T patent/ES2733644T3/es active Active
- 2013-01-25 KR KR1020147023617A patent/KR102064624B1/ko active IP Right Grant
- 2013-01-25 JP JP2014554840A patent/JP6193888B2/ja active Active
-
2015
- 2015-03-16 HK HK15102661.7A patent/HK1202069A1/xx unknown
-
2017
- 2017-04-20 JP JP2017083760A patent/JP2017171667A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2809322B1 (en) | 2019-05-15 |
| CN104203239B (zh) | 2017-09-08 |
| JP2017171667A (ja) | 2017-09-28 |
| CA2862084A1 (en) | 2013-08-01 |
| JP2015511224A (ja) | 2015-04-16 |
| EA028344B1 (ru) | 2017-11-30 |
| KR102064624B1 (ko) | 2020-01-09 |
| CN104203239A (zh) | 2014-12-10 |
| PL2809322T3 (pl) | 2019-11-29 |
| EP2809322A4 (en) | 2015-12-23 |
| ES2733644T3 (es) | 2019-12-02 |
| BR112014018027A2 (xx) | 2017-06-20 |
| KR20140127271A (ko) | 2014-11-03 |
| JP6193888B2 (ja) | 2017-09-06 |
| MX2014008875A (es) | 2014-10-14 |
| WO2013112788A1 (en) | 2013-08-01 |
| MX357834B (es) | 2018-07-26 |
| US9399649B2 (en) | 2016-07-26 |
| BR112014018027B1 (pt) | 2020-10-27 |
| EA201491412A1 (ru) | 2014-12-30 |
| US20150126515A1 (en) | 2015-05-07 |
| CA2862084C (en) | 2021-05-11 |
| EP2809322B9 (en) | 2019-10-30 |
| EP2809322A1 (en) | 2014-12-10 |
| BR112014018027A8 (pt) | 2017-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL254045A0 (en) | Compounds for the treatment of spinal muscular atrophy | |
| HK1202069A1 (en) | Compounds for treating spinal muscular atrophy | |
| HK1200056A1 (en) | Compounds for treating spinal muscular atrophy | |
| HK1202527A1 (en) | Compounds for treating spinal muscular atrophy | |
| HK1202059A1 (en) | Compounds for treating spinal muscular atrophy | |
| HK1215399A1 (zh) | 用於治療脊髓性肌萎縮的化合物 | |
| HRP20181190T1 (hr) | SPOJEVI KOJI SU KORISNI ZA LIJEČENJE AIDS-a | |
| EP2872493A4 (en) | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY | |
| IL262611A (en) | Treatment for lipodystrophy | |
| IL253421B (en) | Compounds for the treatment of fibrosis (Leifat) | |
| EP2828100A4 (en) | SURFACE TREATMENT FOR AN IMPLANT SURFACE | |
| EP2921120A4 (en) | ENDOSCOPE TREATMENT TOOL | |
| EP2904994A4 (en) | spinal orthotic | |
| EP2664286A4 (en) | ENDOSCOPE TREATMENT TOOL | |
| GB201010359D0 (en) | Compounds for treating proliferative disorders | |
| EP2916767A4 (en) | DEVICES FOR TREATING TEETH NECKS | |
| EP2745764A4 (en) | TREATMENT TOOL FOR ENDOSCOPE | |
| ZA201503005B (en) | Ingenol-derived compounds useful for treating cancer | |
| GB201203180D0 (en) | Compounds for treating parvovirus infection | |
| EP2926817A4 (en) | STABLE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OSTEOPOROSIS | |
| HK1209040A1 (en) | Methods for treating vestibulotoxicity | |
| EP2563353A4 (en) | COMPOUNDS FOR ANTIFUNGAL TREATMENT | |
| GB201215527D0 (en) | Compounds for the treatment of muscular dystrophy | |
| GB201009495D0 (en) | Compounds for treating proliferative disorders |